Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
Public ClinicalTrials.gov record NCT03093909. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
Study identification
- NCT ID
- NCT03093909
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Enrollment
- 44 participants
Conditions and interventions
Conditions
- Malignant Neoplasm of Bone and Articular Cartilage
- Malignant Neoplasm of Male Genital Organs
- Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma
- Malignant Neoplasms of Female Genital Organs
- Malignant Neoplasms of Independent (Primary) Multiple Sites
- Malignant Neoplasms of Lip Oral Cavity and Pharynx
- Malignant Neoplasms of Mesothelial and Soft Tissue
- Malignant Neoplasms of Thyroid and Other Endocrine Glands
- Malignant Neoplasms of Urinary Tract
- Melanoma and Other Malignant Neoplasms of Skin
Interventions
- Gemcitabine Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years to 50 Years
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 21, 2017
- Primary completion
- Nov 29, 2027
- Completion
- Nov 29, 2027
- Last update posted
- Nov 9, 2025
2017 – 2027
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03093909, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 9, 2025 · Synced Apr 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03093909 live on ClinicalTrials.gov.